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Abstract 
In newborn intensive care, parents sometimes request treatment that 
professionals regard as ‘futile’ or ‘potentially inappropriate’. One reason not to 
provide potentially inappropriate treatment is because it would be excessively 
costly relative to its benefit.  
Some public health systems around the world assess the cost-effectiveness of 
treatments and selectively fund those treatments that fall within a set threshold. 
In this paper, we explore the application of such thresholds to decisions in 
newborn intensive care, to explore: (1) when a newborn infant’s chance of 
survival is too small; (2) how long treatment should continue; (3) when quality 
of life is too low and (4) when newborn infants are too premature for cost-
effective intensive care. 
This analysis yields some potentially surprising conclusions. Newborn intensive 
care may be cost-effective even in the setting of very low probability of survival, 
quality of life, for protracted periods of time or for the most premature of 
newborns.  
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1. Introduction  
Health practitioners usually have a very strong desire to provide life-sustaining 
treatment (LST) to a newborn infant. Yet there are various situations when 
doctors could regard that treatment as potentially inappropriate. Consider the 
following cases: 
 
 
 
A. A newborn infant has a very severe congenital lung malformation.  
Doctors have attempted to stabilize the infant with specialized forms 
of breathing support; however, he has not responded. Doctors 
believe that there is a more than 95% chance that he will die despite 
maximal treatment. His parents are requesting that full active 
treatment (including, if needed, extracorporeal membrane 
oxygenation) be provided. What chance of survival is too low to 
provide expensive life-support? 
B. A newborn infant, born extremely prematurely has had severe lung 
problems since birth. He has required support with a breathing 
machine in intensive care continuously for 6 months, and appears 
unable to breathe without support from the machine. Doctors and 
nurses in the intensive care unit feel that further treatment is futile, 
but his parents wish treatment to continue. How long is too long to 
provide intensive life-prolonging medical treatment? 
C. A newborn infant has been diagnosed after birth with complex 
congenital heart problems that would usually be treated with major 
cardiac surgery. However, she also has been found to have a 
chromosomal disorder, and if she survives she will have severe 
intellectual disability.  Specialists have suggested that surgery is not 
clinically appropriate, but the infant’s parents are adamant that it 
should be attempted. What level of disability is too great for life-
saving surgery to be provided? 
D. A mother goes into premature labour several months before she is 
due to deliver. She has requested that doctors attempt to save her 
baby, but current guidelines do not recommend resuscitation. At this 
gestation there is a very low chance of survival if intensive care is 
attempted, infants require months of expensive treatment, and a 
significant proportion of survivors have long-term illness or 
impairment. When is a newborn infant too premature for resuscitation 
to be attempted? 
Box 1: When are health professionals justified in declining to provide desired 
treatment?1  
 
Professional guidelines endorse the idea that health professionals are not 
obliged to provide treatment that would be ‘futile’ or ‘potentially 
inappropriate’.1, 2 However, there is no existing agreement on how to define 
futile or inappropriate treatment, nor any clear way to use the concept to answer 
the questions outlined in the box.3 There are often different views about what 
would be in the patient’s interests, based on differing evaluations of the possible 
outcomes, as well as on different value-theories about what grounds such a 
judgment.4 The difficulty in defining futility has led many ethicists to reject the 
concept, and dismiss its use in treatment decisions.5-7  
 
However, distinct from concern for the patient’s interests, a separate reason not 
to provide treatment may be because of concern for distributive justice and the 
need to limit expensive and scarce medical resources. Although most discussion 
about LST in newborn infants focuses on the child’s best interests, (and perhaps 
on the interests and wishes of parents), resources are of central importance in 
intensive care, for newborn infants as for older patients.8, 9 Unfortunately, it is 
sometimes necessary to ration potentially beneficial treatment on the grounds of 
distributive justice.10 
 
                                                        
1 These cases are composite versions of real cases encountered by DW  
One widely used way of deciding between different priorities for funding in a 
public health system is to compare their cost effectiveness. A commonly-used 
metric uses the concept of Quality-Adjusted Life Years (QALY). The QALY is a 
preference-based measure of health outcome that combines length of life and 
health-related quality of life in a single metric. Modelling based economic 
evaluations usually assign probabilities to branches emanating from chance 
nodes with endpoints of each pathway given values or payoffs, such as costs, life 
years or QALYs. This allows analysts to express the cost-effectiveness of new 
treatments in terms of incremental cost per QALY gained. Such calculations can 
be used to decide whether the incremental benefit of an individual treatment is 
sufficiently great, relative to the incremental cost, to provide it. Some countries 
and policy makers have used cost-effectiveness thresholds to efficiently and 
consistently decide between different priorities. In the UK, for example, 
interventions that cost less than a threshold level of £20-30,000 per QALY are 
usually funded by the National Health Service, while those that cost more than 
£30,000 are not usually provided.11, 12  
 
There is considerable ethical debate about the use of cost-effectiveness 
thresholds, and QALYs for deciding between different treatments.13-17 It is not 
the aim of this paper to review those arguments, nor to assess whether the 
incremental cost per QALY metric should be used to decide between medical 
treatments. Rather, the point is that cost-effectiveness thresholds are already 
widely used in many public health systems to decide between different 
treatments. If that approach is justified, on the grounds of consistency, it appears 
that these same thresholds should be applied to other medical interventions. 
What would be the implications of such an approach for decision-making in 
neonatal intensive care? One common objection to cost-effectiveness analysis is 
that it might lead to rationing of life-saving treatment. The results of the analysis 
below might be used to inform debate about what the actual implications would 
be of applying cost-effectiveness thresholds to clinical decisions around 
potentially inappropriate treatment. 
 
 
The focus here on the NICU allows us to set aside some issues that might be 
thought to make decisions more complicated for older individuals (e.g. it 
removes the question of whether priority should be given to those who have 
previously been worse off, or who have experienced a shorter life already). 
However, none of the analysis in this paper should be taken to imply that cost-
effectiveness thresholds should be applied only or preferentially in the NICU. 
Indeed, one feature of standard cost-effectiveness thresholds suggests that 
resource limits far less often provide a justification for withholding treatment in 
the NICU than in adult or paediatric intensive care. If the duration of survival 
after intensive care is longer, the cost-effectiveness of providing life-sustaining 
treatment will be correspondingly greater. 
Since the aim of this paper is to explore ethical questions, we will make some 
assumptions that will simplify analysis, but that would not be part of a formal 
economic evaluation. We will focus on the costs and effects of providing 
intensive care, compared with the option of withdrawing or withholding life-
prolonging treatment (ie the clinical setting for a determination that treatment is 
potentially inappropriate). We will assume that infants not treated will die and 
make the simplifying assumption that an infant who dies in intensive care will 
not have generated economic costs or health consequences. Empirical data for 
examples is drawn from a range of different countries and time points, reflecting 
the availability of data. We will convert currencies to UK pounds (using relevant 
purchasing power parities), but will not adjust for inflation over time. We will 
not apply discounting to future costs or the value of future life-gains. Finally, we 
will assume equal age-weighting for the potential health consequences of 
treatment (i.e. that a year of life saved for a newborn infant is equivalent to a 
year of life saved for an adult). 
2. Low probability treatments 
 
The general formula for assessing cost-effectiveness is given by the following: 
𝐼𝑛𝑐𝑟𝑒𝑚𝑒𝑛𝑡𝑎𝑙 𝐶𝑜𝑠𝑡 𝐸𝑓𝑓𝑒𝑐𝑡𝑖𝑣𝑒𝑛𝑒𝑠𝑠 =
𝐶2̅ − 𝐶1̅
?̅?2 − ?̅?1
=
∆𝐶
∆𝐸
 
where C2 and E2 refer to the mean cost and mean effectiveness of a comparison 
intervention, and C1 and E1 refer to the mean cost and mean effectiveness of the 
reference intervention. We are interested in comparing the alternatives of 
continuing intensive care versus withdrawal of intensive care. If we assume that 
all patients who have treatment withdrawn die (and that this is not associated 
with costs), the formula can be simplified: 
𝐶𝑜𝑠𝑡 𝐸𝑓𝑓𝑒𝑐𝑡𝑖𝑣𝑒𝑛𝑒𝑠𝑠 =
𝐶2̅
?̅?2
 
The effectiveness of continuing intensive care will depend upon the mean 
probability of survival (?̅?), duration of survival (if the patient survives, 𝑑𝑠̅̅ ̅ ) and 
his/her health-related quality of life (hereafter ‘quality of life’ for brevity) (?̅?). 
Cost Effectiveness
=
𝐶𝑜𝑠𝑡 (?̅?)
𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑜𝑓 𝑠𝑢𝑟𝑣𝑖𝑣𝑎𝑙 (?̅?) 𝑥 (𝑑𝑢𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑠𝑢𝑟𝑣𝑖𝑣𝑎𝑙 (?̅?𝑠)𝑥 𝑞𝑢𝑎𝑙𝑖𝑡𝑦 𝑜𝑓 𝑙𝑖𝑓𝑒(?̅?))
 
 
In health care systems that use a fixed cost-effectiveness threshold, the formula 
for cost-effectiveness can be transformed. This can be used to estimate the 
Probability Threshold (PT), where PT is the lowest probability of survival for 
cost-effective life-saving treatment 
 
𝑃𝑇 =
𝐶̅
𝐶𝐸𝑇 𝑥 ?̅?𝑠 𝑥 ?̅?
 
𝐶̅ - mean cost of treatment  
?̅? - mean probability of survival  
𝑑𝑠̅̅ ̅ - duration of survival (if the patient survives) 
?̅? - health-related quality of life  
(These values could be the average value for a cohort of patients, or the expected 
probability/duration/quality for a single patient) 
 
For example, for a newborn infant requiring 20 days of intensive care (at a cost 
of £1000/day), and predicted to survive with full quality of life for 70 years, the 
PT would be ~1%. In other words, based on these assumptions it would be not 
cost-effective to provide this sort of treatment if there were a less than 1% 
chance of normal survival. 
 2.1 Probability threshold for ECMO 
The above assumptions about the cost of treatment are fairly speculative. 
However, this general approach could be used to suggest an answer to the 
question in case A (Box 1). There has been considerable debate in the past about 
whether Extracorporeal Membrane Oxygenation (ECMO) is beneficial and should 
be provided.18 More recently, debate has shifted to which infants should (or 
should not) be offered ECMO.19-22  The average health care cost of ECMO from a 
large neonatal trial was approximately £30 000.23 Using this figure, (and again 
assuming full health-related quality of life for survivors) the PT (ECMO) would be 
1.4%.2  
One specific condition that is sometimes treated with ECMO is Congenital 
Diaphragmatic Hernia. It might be thought that ECMO is not cost-effective for 
infants with severe forms of this condition. A recent US study found the mean 
inpatient hospital cost of providing ECMO to infants with CDH was $193,000 
(£115,000).24  Using this figure, it would be potentially cost-effective to provide 
ECMO to infants with CDH who have a greater than 5% chance of survival. 
(Ongoing health care costs are not included in this estimate, and would be 
expected to influence the Probability Threshold.)  
Infants with CDH who have unfavourable features on pre-natal ultrasound have 
a particularly low predicted survival rate (for example, a lung head ratio <1.0, in 
combination with liver herniation, implying a severe degree of pulmonary 
                                                        
2 It is worth noting that ECMO is usually compared with continuing conventional 
intensive care (without ECMO), and there may be a significant chance of survival 
even without ECMO.  
hypoplasia). It is sometimes thought to be ‘futile’ to provide treatment to this 
group of infants.25 In one study, 3/27 infants with a lung head ratio <1 and liver 
herniation survived (ie 11%).26 This is therefore still potentially above the 
Probability Threshold for cost-effective treatment, and, it would arguably be 
justified to provide treatment despite finite resources. 
 
2.2 Insights  
How does this analysis help? First, treatment with low probability of survival 
may not be cost-effective. If resources are limited it may be reasonable not to 
provide treatment where that chance is below a certain threshold. Standard cost-
effectiveness thresholds used elsewhere in medicine could be used to assess 
where this threshold might lie. 
In neonatal intensive care, given a set of plausible assumptions (and ignoring for 
now questions of quality of life), the Probability threshold is likely to be very low. 
It may be cost-effective to provide treatment even if there is a 99% chance that 
the patient will die. Strikingly, even for infants with extremely severe congenital 
malformations and low chance of survival, (where clinicians sometimes regard 
treatment as potentially inappropriate) it could still be cost-effective to provide 
treatment. 
 
3. Long duration treatment 
When patients receive prolonged treatment in intensive care there may be 
significant concern about the costs and benefit of treatment.27 Cost-effectiveness 
thresholds could be used to calculate the maximum duration of cost-effective 
intensive care, the Duration Threshold (DT). 
𝐷𝑇 =
𝐶𝐸𝑇 𝑥 ?̅?𝑠 𝑥 ?̅? 𝑥 ?̅?
 𝐶𝑑̅̅ ̅
 
𝐶̅d is the daily cost of treatment. 
 
Based on this formula, we could estimate an answer to the question posed in 
case B about how long it may be appropriate to continue intensive care (Box 1). 
One older study suggested that 50% of newborn infants requiring mechanical 
ventilation for more than 6 months survived to age 3.28 In a large US cohort 
study, 50% of extremely low birth weight infants ventilated for more than 4 
months survived.29 Based on that data, for infants with an estimated 50% chance 
of survival, the Duration Threshold for neonatal intensive care (assuming full 
duration of adult life and full quality of life) would be over 1000 days. 
 
3.1 Duration threshold for ECMO 
A similar analysis could be conducted for other intensive medical treatments. 
Table 1 presents an assessment of the duration of cost-effective ECMO for 
newborn infants, depending on the daily cost of ECMO, and the probability of 
survival (if ECMO is provided). This treatment is usually provided for periods of 
1-2 weeks, but sometimes for longer than 1 month. This table suggests that it 
could be cost-effective to provide ECMO for as long as 6 weeks, even at a higher 
cost estimate, if there is a 25% chance of survival full life expectancy. This might 
be a realistic assumption. In one study of prolonged ECMO in children, 22% of 
children receiving more than 28 days of ECMO survived to discharge from 
hospital.30 However, if there is a lower life expectancy, the Duration threshold 
falls (Table 2). For patients with a 25% chance of survival (and life expectancy of 
10 years), it may not be cost-effective to provide ECMO for more than 6 days.  
 
[Insert Tables 1 and 2 here] 31 
3.3 Insights 
How does this analysis help? First, cost-effectiveness based criteria could be 
used to determine a threshold for the maximum duration of treatment. Analysis 
suggests that in neonatal intensive care prolonged mechanical ventilation or 
ECMO may be cost-effective even if long periods of treatment are required. Based 
on estimates of 50% survival, intensive care may be worth providing for several 
years to a newborn. Likewise, it may be cost-effective to provide 6-12 weeks of 
ECMO to a newborn infant. 
These findings may be counterintuitive. One important limitation is the 
assumption of a normal lifespan. There is little or no evidence on the adult 
longevity of survivors of neonatal intensive care.32 If duration of survival is 
reduced, that would reduce the duration of cost-effective treatment. 
We have also assumed normal quality of life. That may be important, since many 
authors are critical of existing methods for quantifying quality of life – 
particularly if such measures were to be used in rationing health care.13, 33, 34  
However, a number of health care systems do incorporate measures of quality of 
life into cost-effectiveness assessments. What would be the implications of this 
for the treatment decisions in newborn intensive care? 
 
4. Reduced Quality of Life 
If survival is associated with reduced quality of life, and if were acceptable to 
incorporate quality of life into cost-effectiveness calculations, we could calculate 
a Quality Threshold (QT) – a minimum anticipated health-related quality of life 
for cost-effective intensive care. 
 
 𝑄𝑇 =
𝐶̅
𝐶𝐸𝑇 ×  ?̅?  ×  𝑑𝑠̅̅ ̅
  
𝐶̅ – total cost of treatment in intensive care 
 
For example, one large UK modeling study of the costs of treatment in neonatal 
intensive care found an average inpatient cost for extremely preterm infants 
admitted to NICU of £87552.35  Based on this cost, the value of QT for an infant 
with a 50% chance of survival would be 0.08. (By comparison, the average value 
for health-related quality of life in a cohort of adolescents with cerebral palsy 
was 0.42).36 In other words, it could be cost-effective to provide treatment to an 
extremely preterm infant even in the setting of substantially reduced predicted 
quality of life. 
This includes only the acute in-hospital costs. There may be concerns about 
whether it is ethical to incorporate additional costs through childhood in 
decisions about providing neonatal intensive care. However, if the costs of 
ongoing treatment were included, we could calculate a further estimate of QT. In 
a UK analysis of costs for preterm infants, the average cost per year for children 
with severe disability (once they reached primary school) was approximately 
£12000.35 Combining average acute and ongoing costs through childhood, and 
focusing only on outcome to age 18, this would yield a value for QT of 0.47. Note 
that this value for QT is close to the average value for children with cerebral 
palsy, and to the value of health related quality of life used in some studies for 
surviving ex-premature infants with severe disability (0.4).37 This suggests that 
provision of life-saving treatment to extremely preterm infants could be cost-
effective, even in the setting of predicted certain severe disability.  
4.1 Cardiac surgery for infants with severe disability 
One example of this question is whether it would be potentially inappropriate for 
children with major chromosomal disorders such as Trisomy 18 to receive 
complex cardiac surgery.38 Trisomy 18 is associated with a high rate of mortality 
(approximately 90% of infants die in the first year of life), but all surviving 
children have profound cognitive disability.39 Should expensive cardiac surgery 
be provided to children with such severe disability? An assessment of the cost-
effectiveness of treatment will depend on the value placed on survival with 
severe impairment. It will also depend on how long a child is predicted to live 
with and without cardiac surgery. That can be difficult to estimate, since 
available data are influenced by selection bias and non-treatment decisions.40  
From other data on children with disability, one estimate is that the median life 
expectancy (for children with severe cerebral palsy) is approximately 10 years 
for children with severe mixed disability, 15 years for children with severe 
motor disability, 35 years for children with severe cognitive disability.41 
 
A recent paper from the US provides a useful list of in-hospital costs for a range 
of paediatric cardiac procedures.42  We can determine from these values the 
Commented [DW1]: Includes from Mangham Average 
inpatient cost for preterm infants (87552), plus hospital 
costs in first years of life – average 4000, plus 1200/year 
X3 for preschool years and 12000/year x13 for school 
years 
Duration of survival 18 years, probability 1 
minimum quality of life that would render treatment cost effective (Table 3). 
(This is a conservative estimate, since some infants may survive without 
surgery). 
[Insert Table 3 here] 42 
 
From this table, major cardiac surgical procedures could be cost-effective for 
children with severe disability with a health-related quality of life of 0.4 or 
greater. If it were acceptable to include ongoing health care costs through 
childhood, the values for the Quality Threshold or the Survival Threshold would 
rise, implying that a better prognosis would be required for surgery to be 
potentially appropriate.  
 
4.2 Insights 
 
How does this analysis help? As already noted, the inclusion of quality of life in 
cost-effectiveness calculations raises questions about whether this would be 
unjustly discriminatory,33, 43 but also about how to assess the quality of life of 
individuals born in states of disability. If quality of life is included in cost 
effectiveness calculations, some expensive treatments will be excluded. 
However, at least if basic treatments, and ongoing medical care are set aside 
from resource allocation decisions, some acute expensive interventions may be 
cost-effective despite severely reduced quality of life – for example cardiac 
surgery for complex congenital heart disease.  
5. Intensive care in the setting of reduced probability of 
survival, high cost, and quality of life 
 
Our analysis has artificially isolated individual variables. However, often 
questions about resuscitation raise a mix of issues. Treatment may be highly 
expensive acutely and in the long term. There is a reduced chance of survival. 
Surviving children may have reduced quality of life. For example, this potentially 
applies to infants at the margins of viability. 
5.1 Should resuscitation be provided for 22-week gestation infants? 
 
In the United States, there is wide variation in the rates of active treatment for 
extremely premature infants born at 22 weeks of gestation,44 which appears to 
reflect a judgment by some that treatment is potentially inappropriate. In the UK, 
resuscitation is not recommended for infants born before 23 weeks’ gestation.45 
Although economic costs were not a factor cited in the development of that 
policy, this view might be justified if it were too expensive to treat infants this 
premature relative to the outcome. 
The relative paucity of data (and the small number of infants actively treated), 
makes it difficult to assess the costs of treatment for 22 week infants.46 However, 
it may be possible to extrapolate from a slightly less immature cohort. Recent 
modelling, based on US data, incorporated estimates of survival rates, acute 
hospital and long-term care costs as well as reduced quality of life in a 
proportion of survivors. This analysis suggests that selective or routine 
resuscitation and intensive care falls within cost-effectiveness thresholds (of 
$100,000/QALY) for 23 week infants as long as the chance of survival is above 
5%.47 If the costs are similar, that may imply that resuscitation is cost-effective 
for 22 week infants, since the actual rates of survival at this gestation for infants 
admitted to intensive care appears closer to 20%.44 (In fact, the costs per infant 
may be lower in more immature infants, since a high proportion of infants die 
early in the neonatal period and do not incur substantial costs.46).  
This appears to suggest that based on available data, provision of resuscitation 
and intensive care is cost-effective even at gestations where treatment is often 
withheld. However, it may not be cost-effective to provide intensive care to 
subgroups of extremely premature infants, for example with very low chances of 
survival (<5%).    
 
6. Conclusions 
In this paper, we have explored how cost-effectiveness analysis could be applied 
to clinical questions about when treatment is potentially inappropriate on the 
grounds of excessive cost relative to benefit. We have not argued that cost-
effectiveness should be applied in this way, but aimed to assess what the 
implications would be for developed countries if it were acceptable to ration 
treatment in this way. Although we have derived some specific answers about 
where the thresholds might lie, these should be seen as a starting point for 
debate rather than being applied to clinical practice. The underlying assumptions 
– about the costs of treatment, about the outcome of therapy, and about the cost-
effectiveness threshold, would need to be assessed and potentially modified in a 
particular situation. For many of these questions in newborn intensive care, 
there is limited available data on the costs or on the outcome of treatment – 
indicating the need for further careful research to inform decisions.  
 
We have used a particular cost-effectiveness threshold in the above calculations, 
however, particular health systems may use a higher or lower threshold. 
Alternatively, they may choose to apply what is sometimes called the ‘rule of 
rescue’, 48 49 and use a higher threshold for intensive care than for other medical 
treatments. If that were the case, the lessons learned from the foregoing analysis 
are likely to still apply – though the specific thresholds would vary. Table 4 
provides corresponding answers to some of the questions asked in the cases at 
the start of this paper at higher (and lower) levels of the cost-effectiveness 
threshold.  
 
[Insert Table 4 here] 
 
The foregoing analysis highlights some tentative conclusions that may appear 
counterintuitive or challenge existing practice. First, the potential long survival 
following newborn intensive care means that cost-effectiveness-derived 
thresholds in that setting will yield more treatment, longer treatment, and 
treatment in a wider range of cases than is the case for older children or adults. 
This may conflict with some current views about whether or not resuscitation 
should be provided to some of the sickest and most premature newborn infants. 
Conversely, it may highlight an apparent disconnect between current practice 
and ethical theory, since there is evidence that treatment thresholds in 
paediatric intensive care are more generous than in newborn intensive care (in 
the PICU, doctors appear to be less inclined to limit treatment in the face of poor 
prognosis compared with NICU).50 One possibility, not discussed in this paper, is 
that different value is placed on saving lives at different points in the life-span.51 
If such an approach were followed, that would apply a lower (or a higher) cost-
effectiveness threshold to newborn infants. 
The most controversial feature of applying cost-effectiveness thresholds to 
intensive care is the apparent implication that life-sustaining treatment would be 
denied to some patients with predicted disability. The foregoing analysis 
suggests that if it is justified to include quality of life in cost-effectiveness 
analysis, in newborn intensive care treatment may be limited on resource 
grounds only where future quality of life is predicted to be very low. Depending 
on whether or not long-term care costs are included, major interventions are still 
potentially cost-effective, even in the setting of certain severe predicted 
disability. 
One fear that is sometimes expressed about rationing in general, and cost-
effectiveness analysis in particular, is that it would lead to withholding of life-
sustaining treatment from many patients who stand to benefit. The above 
analysis suggests that this is not the case, at least in the context of newborn 
intensive care.  
The application of cost-effectiveness analysis may provide an ethically defensible 
way to determine when treatment would be potentially inappropriate. However, 
it may also, in a significant number of cases, challenge and contradict existing 
implicit rationing; it may support and promote access to desired medical 
treatment. 
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 Probability 
of survival 
Duration Threshold - Days 
(Daily cost of ECMO £6000) 
Duration Threshold - 
Days (Daily cost of 
ECMO £12000) 
0.1 35 18 
0.25 88 44 
0.5 175 88 
0.75 263 131 
 
Table 1: Duration threshold for maximum cost-effective ECMO at different values 
for the probability of survival. Assuming that if ECMO is withdrawn prematurely 
that the patient will not survive. Based on daily costs of ECMO as a bridge to 
transplant for children of £6-12000 per day.31   
  
 Life expectancy DT 
70 44 
60 38 
50 31 
40 25 
30 19 
20 13 
10 6 
 
Table 2 Duration threshold for ECMO (at a daily cost of £12000) based on 
predicted life-expectancy, for a patient with 25% chance of survival. 
  
  Procedure 
cost (USD) 
Procedure 
cost 
(pounds) QT (10) 
ST (0.4) 
Atrial Septal Defect repair 25499 15554 0.05 1.3 
Ventricular septal defect 
repair 33679 20544 0.07 1.7 
Tetralogy of Fallot repair 44318 27034 0.09 2.3 
Fontan 51464 31393 0.10 2.6 
Arterial Switch 94902 57890 0.19 4.8 
Truncus repair 133006 81134 0.27 6.8 
Norwood 165168 100752 0.34 8.4 
Table 3: Median costs of cardiac surgery in childhood42 and the Quality/Survival 
thresholds for children with either predicted reduced lifespan, or predicted 
reduced quality of life, ignoring ongoing health care costs.  
QT(10) – Minimum predicted quality of life consistent with cost-effective 
treatment, assuming predicted survival of 10 years 
ST(0.4) - Minimum duration of survival for cost-effective treatment, assuming a 
quality of life of 0.4 
  
Incremental Cost-
effectiveness threshold 
(pounds) 
 
 
10 000 20 000 30 000 50 000 100 000 
What probability of survival is too 
low to provide ECMO? (see section 
2) – Case A 
4.2% 2.1% 1.4% 0.8% 0.4% 
What duration of mechanical 
ventilation is too long in neonatal 
intensive care? (see section 3) – 
Case B 
350 days 700 
days 
1050 
days 
1750 
days 
3500 
days 
What is the lowest quality of life to 
provide a Fontan repair? (see 
section 4) – Case C 
0.3 0.15 0.1 0.06 0.03 
Table 4. Summary of thresholds for cost-effective treatment, with alternative 
answers at different cost-effectiveness thresholds. Assumptions are described in 
the relevant sections of the text. Answers in bold are those provided in the text 
for a standard cost-effectiveness threshold of £30,000/QALY.  
 
